VC Firms Seek New FDA Review Path, User Fee For "Novel" Devices
This article was originally published in The Gray Sheet
Executive Summary
The National Venture Capital Association is in discussions with senior CDRH officials about establishing a separate, more efficient pre-market review pathway for especially novel devices, supported by a supplemental user fee